P
Paratek Pharmaceuticals Inc
F:N4CN
Paratek Pharmaceuticals Inc
F:N4CN
Price:
2.024
EUR
Market Closed
Market Cap:
€115.9m
Balance Sheet
Balance Sheet Decomposition
Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc
Balance Sheet
Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1
|
96
|
131
|
53
|
35
|
47
|
102
|
105
|
80
|
34
|
|
| Cash |
1
|
96
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
131
|
53
|
35
|
47
|
102
|
105
|
80
|
34
|
|
| Short-Term Investments |
0
|
0
|
0
|
75
|
116
|
203
|
113
|
20
|
15
|
0
|
|
| Total Receivables |
0
|
4
|
1
|
0
|
6
|
0
|
10
|
16
|
33
|
78
|
|
| Accounts Receivables |
0
|
4
|
1
|
0
|
6
|
0
|
10
|
16
|
29
|
75
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
12
|
15
|
11
|
17
|
|
| Other Current Assets |
0
|
1
|
10
|
4
|
3
|
5
|
7
|
9
|
12
|
8
|
|
| Total Current Assets |
1
|
101
|
142
|
132
|
161
|
255
|
243
|
164
|
152
|
137
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
2
|
1
|
4
|
3
|
3
|
2
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
2
|
1
|
4
|
3
|
3
|
2
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
2
|
2
|
|
| Intangible Assets |
0
|
5
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
43
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
3
|
1
|
1
|
1
|
1
|
3
|
9
|
28
|
32
|
|
| Other Assets |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
1
N/A
|
110
+8 362%
|
146
+33%
|
136
-7%
|
164
+21%
|
300
+83%
|
251
-16%
|
177
-30%
|
184
+4%
|
173
-6%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
8
|
1
|
1
|
5
|
4
|
2
|
4
|
2
|
5
|
5
|
|
| Accrued Liabilities |
5
|
3
|
17
|
16
|
13
|
16
|
18
|
22
|
24
|
32
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
23
|
0
|
3
|
0
|
0
|
0
|
2
|
1
|
2
|
0
|
|
| Total Current Liabilities |
35
|
4
|
21
|
20
|
17
|
18
|
24
|
24
|
31
|
37
|
|
| Long-Term Debt |
0
|
5
|
21
|
40
|
59
|
229
|
261
|
251
|
254
|
257
|
|
| Other Liabilities |
0
|
6
|
4
|
4
|
5
|
6
|
6
|
5
|
26
|
49
|
|
| Total Liabilities |
35
N/A
|
15
-58%
|
45
+204%
|
64
+43%
|
81
+27%
|
253
+211%
|
291
+15%
|
279
-4%
|
312
+12%
|
344
+10%
|
|
| Equity | |||||||||||
| Common Stock |
81
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
180
|
198
|
269
|
380
|
470
|
583
|
711
|
808
|
867
|
930
|
|
| Additional Paid In Capital |
66
|
293
|
370
|
452
|
553
|
630
|
672
|
706
|
739
|
759
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
34
N/A
|
95
N/A
|
101
+6%
|
72
-29%
|
83
+15%
|
48
-42%
|
40
N/A
|
102
-158%
|
128
-25%
|
171
-34%
|
|
| Total Liabilities & Equity |
1
N/A
|
110
+8 362%
|
146
+33%
|
136
-7%
|
164
+21%
|
300
+83%
|
251
-16%
|
177
-30%
|
184
+4%
|
173
-6%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
14
|
18
|
23
|
28
|
32
|
40
|
47
|
52
|
57
|
|
Switch to:
Switch to:
See Also
Discover More
